biosensors
XPhyto to Acquire POC Dx Development Partner 3a-diagnostics for $4.6M
XPhyto said the acquisition will provide it with a pipeline of biosensor products and facilitate its expansion into point-of-care biosensor diagnostic markets.
The method uses graphene-coated silica particles fused to complementary RNA to register impedance changes in the presence of viruses.
A team of Swedish researchers has received $3.3 million to develop a new nanotechnology platform for detecting blood-borne markers in lung and breast cancer.
The company's core technology involves the use of cultured cells as biosensors to detect expression levels of genes associated with the disease.
The team showed the approach could successfully monitor cytokines in infants after heart surgery, and is involved now in a larger clinical study expanding this research.